{
    "clinical_study": {
        "@rank": "87464", 
        "arm_group": [
            {
                "arm_group_label": "group 3", 
                "arm_group_type": "Experimental", 
                "description": "intravenous iron and EPO"
            }, 
            {
                "arm_group_label": "group 1", 
                "arm_group_type": "Placebo Comparator", 
                "description": "no intravenous iron or EPO"
            }, 
            {
                "arm_group_label": "group 2", 
                "arm_group_type": "Experimental", 
                "description": "intravenous iton but no EPO"
            }
        ], 
        "brief_summary": {
            "textblock": "There are wide variations in iron supplementation practices in NICU.Guidelines on paediatric\n      Parenteral nutrition suggested the dose of 200\u03bcg/kg.d iron by parenteral nutrition.In our\n      early study serum ferritin and TIBC were not statistically significant before and after\n      intervention by used the dose of intravenous iron.In our study,we find twhether iron\n      combined EPO can improve iron state in preterm."
        }, 
        "brief_title": "Effects of Early Short-term Intravenous Iron Supplements Combinded EPO in Preterm Infants", 
        "condition": "Preterm Anemia", 
        "condition_browse": {
            "mesh_term": "Anemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Preterm infants with birth weight less than 2.5kg Have parenteral nutrition\n             indication With written informed consent of parents or guardian\n\n        Exclusion Criteria:\n\n          -  Kidney and liver function abnormal have hemolytic disease have hemorrhagic disease\n             have Serious congenital malformation have septicemia have plethora newborn use TPN\n             less than ten days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "24 Hours", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "138", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02060851", 
            "org_study_id": "kunshan002"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "group 3", 
                    "group 2"
                ], 
                "intervention_name": "Iron sucrose", 
                "intervention_type": "Drug", 
                "other_name": "Cosmofer"
            }, 
            {
                "arm_group_label": "group 3", 
                "intervention_name": "EPO", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ferric oxide, saccharated", 
                "Iron"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "EPO", 
            "Intravenous iron", 
            "iron storage", 
            "preterm anemia"
        ], 
        "lastchanged_date": "February 9, 2014", 
        "location": {
            "contact": {
                "email": "mumeer@126.com", 
                "last_name": "Hua Wang, MD", 
                "phone": "+8618913261020"
            }, 
            "facility": {
                "address": {
                    "city": "Kunshan, ,", 
                    "country": "China", 
                    "state": "Jiangsu", 
                    "zip": "215300"
                }, 
                "name": "Kunshan First Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "overall_contact": {
            "email": "mumeer@126.com", 
            "last_name": "Hua Wang, MD", 
            "phone": "0512-57027091"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Hematological evaluation including RBC, Hb, MCV, MCH, MCHC, RET, CRP were mesured before and after the intervention. The three groups were all peripheral blood.", 
            "measure": "Hematological evaluation", 
            "safety_issue": "No", 
            "time_frame": "up to 2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02060851"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kunshan First People's Hospital  Affiliated to Jiangsu University", 
            "investigator_full_name": "Wang Hua", 
            "investigator_title": "Ethics Committee of Kunshan First People's Hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Iron storage evaluation including ferritin, serum iron, TIBC on the days were measured before and after the intervention.", 
            "measure": "Iron storage", 
            "safety_issue": "No", 
            "time_frame": "up to 2 weeks"
        }, 
        "source": "Kunshan First People's Hospital  Affiliated to Jiangsu University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kunshan First People's Hospital  Affiliated to Jiangsu University", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}